FDA's drug database shows a supplement dated 25 September to Eli Lilly's application for baricitinib, the oral JAK inhibitor licensed in the US for severe alopecia areata among other indications. The listing does not state what the supplement covers; supplements range from manufacturing and labelling updates to new indications.
Until the label change is published, there is nothing for prescribers to act on. A licence supplement is not a new indication, and it should not be read as one.
- Treat this as an administrative listing until the updated label is published.
- Check the current baricitinib label for any changes before your next prescription review.
- Continue standard JAK inhibitor screening and monitoring for patients on baricitinib.
Why it matters
Supplements sometimes carry label changes that affect monitoring, so it is worth watching for the published label.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free